107 related articles for article (PubMed ID: 1290703)
1. Tumour radiosensitization with the halogenated pyrimidines 5'-bromo- and 5'-iododeoxyuridine.
Epstein AH; Cook JA; Goffman T; Glatstein E
BJR Suppl; 1992; 24():209-14. PubMed ID: 1290703
[No Abstract] [Full Text] [Related]
2. The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers.
Kinsella TJ; Mitchell JB; Russo A; Morstyn G; Glatstein E
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1399-406. PubMed ID: 6381432
[TBL] [Abstract][Full Text] [Related]
3. [Effect of BAR therapy in a case of malignant glioma with extracranial metastasis].
Kanno T; Moriyama M; Kagawa M; To T; Ishimori S
No To Shinkei; 1970 Oct; 22(10):1187-91. PubMed ID: 5536188
[No Abstract] [Full Text] [Related]
4. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors, and high grade sarcomas after continuous intravenous infusions of 5-iododeoxyuridine.
Cook JA; Glass J; Lebovics R; Bobo H; Pass H; DeLaney TF; Oldfield EH; Mitchell JB; Glatstein E; Goffman TE
Cancer Res; 1992 Feb; 52(3):719-25. PubMed ID: 1732059
[TBL] [Abstract][Full Text] [Related]
5. Radiosensitization of brain tumor cells with a thymidine analogue (bromouridine).
Sano K; Hoshino T; Nagai M
J Neurosurg; 1968 Jun; 28(6):530-8. PubMed ID: 4233585
[No Abstract] [Full Text] [Related]
6. Halogenated pyrimidines as radiosensitizers for high grade glioma: revisited.
Rodriguez R; Kinsella TJ
Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):859-62; discussion 865. PubMed ID: 1651310
[No Abstract] [Full Text] [Related]
7. Clinical use of radiation sensitizing agents.
Goffinet DR; Bagshaw MA
Cancer Treat Rev; 1974 Mar; 1(1):15-26. PubMed ID: 4143475
[No Abstract] [Full Text] [Related]
8. [Radiation sensitization of brain neoplasms by haloid analogs of pyrimidine bases].
Lokshina AM; Pelevina II
Med Radiol (Mosk); 1973 Mar; 18(3):70-7. PubMed ID: 4267617
[No Abstract] [Full Text] [Related]
9. Radiobiology and clinical application of halogenated pyrimidine radiosensitizers.
Mitchell JB; Russo A; Cook JA; Straus KL; Glatstein E
Int J Radiat Biol; 1989 Nov; 56(5):827-36. PubMed ID: 2573682
[TBL] [Abstract][Full Text] [Related]
10. Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme.
Jackson D; Kinsella T; Rowland J; Wright D; Katz D; Main D; Collins J; Kornblith P; Glatstein E
Am J Clin Oncol; 1987 Oct; 10(5):437-43. PubMed ID: 2821790
[TBL] [Abstract][Full Text] [Related]
11. Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma.
Williams JA; Dillehay LE; Tabassi K; Sipos E; Fahlman C; Brem H
J Neurooncol; 1997 May; 32(3):181-92. PubMed ID: 9049879
[TBL] [Abstract][Full Text] [Related]
12. The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer.
Lawrence TS; Davis MA; Maybaum J; Mukhopadhyay SK; Stetson PL; Normolle DP; McKeever PE; Ensminger WD
Cancer Res; 1992 Jul; 52(13):3698-704. PubMed ID: 1617642
[TBL] [Abstract][Full Text] [Related]
13. Recent and current investigations of radiation therapy of malignant gliomas.
Nelson DF; Urtasun RC; Saunders WM; Gutin PH; Sheline GE
Semin Oncol; 1986 Mar; 13(1):46-55. PubMed ID: 3082011
[No Abstract] [Full Text] [Related]
14. BUdR radiosensitization in anaplastic astrocytoma.
Yung WK
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1105-6. PubMed ID: 10613300
[No Abstract] [Full Text] [Related]
15. Halogenated pyrimidine sensitization of low dose rate irradiation in human malignant glioma.
McLaughlin PW; Mancini WR; Stetson PL; Greenberg HS; Nguyen N; Seabury H; Heidorn DB; Lawrence TS
Int J Radiat Oncol Biol Phys; 1993 Jul; 26(4):637-42. PubMed ID: 8330994
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of intravenous bromodeoxyuridine used concomitantly with radiation therapy in patients with primary malignant brain tumors.
Phuphanich S; Levin EM; Levin VA
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1769-72. PubMed ID: 6480461
[TBL] [Abstract][Full Text] [Related]
17. [Significance of the combined use of radiosensitizing agents on radiotherapy of malignant encephaloma].
Hoshino T
Rinsho Hoshasen; 1968 Nov; 13(11):885-91. PubMed ID: 4304555
[No Abstract] [Full Text] [Related]
18. Long-term follow-up on National Cancer Institute Phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation.
Goffman TE; Dachowski LJ; Bobo H; Oldfield EH; Steinberg SM; Cook J; Mitchell JB; Katz D; Smith R; Glatstein E
J Clin Oncol; 1992 Feb; 10(2):264-8. PubMed ID: 1310102
[TBL] [Abstract][Full Text] [Related]
19. A Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation.
Kinsella TJ; Russo A; Mitchell JB; Rowland J; Jenkins J; Schwade J; Myers CE; Collins JM; Speyer J; Kornblith P
Int J Radiat Oncol Biol Phys; 1984 Jan; 10(1):69-76. PubMed ID: 6321412
[TBL] [Abstract][Full Text] [Related]
20. Continuous infusion of halogenated pyrimidines.
Rodriguez R; Miller E; Fowler JF; Kinsella TJ
Int J Radiat Oncol Biol Phys; 1991 Jun; 20(6):1380-2. PubMed ID: 2045313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
